Journal of Neurology

, Volume 258, Issue 1, pp 3–13

Tuberculous meningitis in patients infected with human immunodeficiency virus

Review

Abstract

Tuberculosis is the most common opportunistic infection in human immunodeficiency virus (HIV) infected persons. HIV-infected patients have a high incidence of tuberculous meningitis as well. The exact incidence and prevalence of tuberculous meningitis in HIV-infected patients are not known. HIV infection does not significantly alter the clinical manifestations, laboratory, radiographic findings, or the response to therapy. Still, some differences have been noted. For example, the histopathological examination of exudates in HIV-infected patients shows fewer lymphocytes, epithelioid cells, and Langhan’s type of giant cells. Larger numbers of acid-fast bacilli may be seen in the cerebral parenchyma and meninges. The chest radiograph is abnormal in up to 46% of patients with tuberculous meningitis. Tuberculous meningitis is likely to present with cerebral infarcts and mass lesions. Cryptococcal meningitis is important in differential diagnosis. The recommended duration of treatment in HIV-infected patients is 9–12 months. The benefit of adjunctive corticosteroids is uncertain. Antiretroviral therapy and antituberculosis treatment should be initiated at the same time, regardless of CD4 cell counts. Tuberculous meningitis may be a manifestation of paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome. Some studies have demonstrated a significant impact of HIV co-infection on mortality from tuberculous meningitis. HIV-infected patients with multidrug-resistant tuberculous meningitis have significantly higher mortality. The best way to prevent HIV-associated tuberculous meningitis is to diagnose and isolate infectious cases of tuberculosis promptly and administer appropriate treatment.

Keywords

BCG vaccination Extrapulmonary tuberculosis Human immunodeficiency virus Dexamethasone Mycobacterium tuberculosis 

References

  1. 1.
    Garg RK (2010) Tuberculous meningitis. Acta Neurol Scand 122:75–90PubMedGoogle Scholar
  2. 2.
    Shaw JE, Pasipanodya JG, Gumbo T (2010) Meningeal tuberculosis: high long-term mortality despite standard therapy. Medicine (Baltimore) 89:189–195CrossRefGoogle Scholar
  3. 3.
    World Health Organization and UNAIDS (2008) Global summary of the HIV/AIDS epidemic. http://www.who.int/hiv/data/2009_global_summary.gif. Accessed 6 Apr 2010
  4. 4.
    World Health Organization (2010) Global tuberculosis control: a short update to the 2009 report. http://www.who.int/tb/publications/global_report/2009/update/en/index.html. Accessed 6 Apr 2010
  5. 5.
    World Health Organization (2010) Tuberculosis and HIV. http://www.who.int/hiv/topics/tb/en/index.html. Accessed 16 July 2010
  6. 6.
    Harries A, Maher D, Graham S (2004) TB/HIV: a clinical manual. World Health Organization. (WHO/HTM/TB/2004.329). http://whqlibdoc.who.int/publications/2004/9241546344.pdf.pdf. Accessed 6 Apr 2010
  7. 7.
    Peto HM, Pratt RH, Harrington TA, LoBue PA, Armstrong LR (2009) Epidemiology of extrapulmonary tuberculosis in the United States, 1993–2006. Clin Infect Dis 49:1350–1357CrossRefPubMedGoogle Scholar
  8. 8.
    Kruijshaar ME, Abubakar I (2009) Increase in extrapulmonary tuberculosis in England and Wales 1999–2006. Thorax 64:1090–1095CrossRefPubMedGoogle Scholar
  9. 9.
    Attili VS, Singh VP, Rai M, Varma DV, Sundar S (2005) Evaluation of the status of tuberculosis as part of the clinical case definition of AIDS in India. Postgrad Med J 81:404–408CrossRefPubMedGoogle Scholar
  10. 10.
    Helbok R, Pongpakdee S, Yenjun S, Dent W, Beer R, Lackner P et al (2006) Chronic meningitis in Thailand. Clinical characteristics, laboratory data and outcome in patients with specific reference to tuberculosis and cryptococcosis. Neuroepidemiology 26:37–44CrossRefPubMedGoogle Scholar
  11. 11.
    Parwati I, van Crevel R, van Soolingen D (2010) Possible underlying mechanisms for successful emergence of the Mycobacterium tuberculosis Beijing genotype strains. Lancet Infect Dis 10:103–111CrossRefPubMedGoogle Scholar
  12. 12.
    Yorsangsukkamol J, Chaiprasert A, Prammananan T, Palittapongarnpim P, Limsoontarakul S, Prayoonwiwat N (2009) Molecular analysis of Mycobacterium tuberculosis from tuberculous meningitis patients in Thailand. Tuberculosis (Edinb) 89:304–309CrossRefGoogle Scholar
  13. 13.
    Caws M, Thwaites G, Stepniewska K, Nguyen TN, Nguyen TH, Nguyen TP et al (2006) Beijing genotype of Mycobacterium tuberculosis is significantly associated with human immunodeficiency virus infection and multidrug resistance in cases of tuberculous meningitis. J Clin Microbiol 44:3934–3939CrossRefPubMedGoogle Scholar
  14. 14.
    Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, Raviglione MC et al (2003) The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 163:1009–1021CrossRefPubMedGoogle Scholar
  15. 15.
    Golden MP, Vikram HR (2005) Extrapulmonary tuberculosis: an overview. Am Fam Physician 72:1761–1768PubMedGoogle Scholar
  16. 16.
    Day JH, Grant AD, Fielding KL, Morris L, Moloi V, Charalambous S et al (2004) Does tuberculosis increase HIV load? J Infect Dis 190:1677–1684CrossRefPubMedGoogle Scholar
  17. 17.
    Patel NR, Swan K, Li X, Tachado SD, Koziel H (2009) Impaired M tuberculosis-mediated apoptosis in alveolar macrophages from HIV+ persons: potential role of IL-10 and BCL-3. J Leukoc Biol 86:53–60CrossRefPubMedGoogle Scholar
  18. 18.
    Patel NR, Zhu J, Tachado SD, Zhang J, Wan Z, Saukkonen J, Koziel H (2007) HIV impairs TNF-alpha mediated macrophage apoptotic response to Mycobacterium tuberculosis. J Immunol 179:6973–6980PubMedGoogle Scholar
  19. 19.
    Maddocks S, Scandurra GM, Nourse C, Bye C, Williams RB, Slobedman B et al (2009) Gene expression in HIV-1/Mycobacterium tuberculosis co-infected macrophages is dominated by M. tuberculosis. Tuberculosis (Edinb) 89:285–293CrossRefGoogle Scholar
  20. 20.
    Geldmacher C, Schuetz A, Ngwenyama N, Casazza JP, Sanga E, Saathoff E et al (2008) Early depletion of Mycobacterium tuberculosis-specific T helper 1 cell responses after HIV-1 infection. J Infect Dis 198:1590–1598CrossRefPubMedGoogle Scholar
  21. 21.
    Rich AR, McCordock HA (1933) Pathogenesis of tubercular meningitis. Bull John Hopkins Hosp 52:5–13Google Scholar
  22. 22.
    Be NA, Kim KS, Bishai WR, Jain SK (2009) Pathogenesis of central nervous system tuberculosis. Curr Mol Med 9:94–99CrossRefPubMedGoogle Scholar
  23. 23.
    Patel VB, Bhigjee AI, Bill PL, Connolly CA (2002) Cytokine profiles in HIV seropositive patients with tuberculous meningitis. J Neurol Neurosurg Psychiatry 73:598–599CrossRefPubMedGoogle Scholar
  24. 24.
    Simmons CP, Thwaites GE, Quyen NT, Torok E, Hoang DM, Chau TT et al (2006) Pretreatment intracerebral and peripheral blood immune responses in Vietnamese adults with tuberculous meningitis: diagnostic value and relationship to disease severity and outcome. J Immunol 176:2007–2014PubMedGoogle Scholar
  25. 25.
    Katrak SM, Shembalkar PK, Bijwe SR, Bhandarkar LD (2000) The clinical, radiological and pathological profile of tuberculous meningitis in patients with and without human immunodeficiency virus infection. J Neurol Sci 181:118–126CrossRefPubMedGoogle Scholar
  26. 26.
    Thwaites GE, Duc Bang N, Huy Dung N, Hoang Thi Q, Do Thi T, Nguyen TC et al (2005) The influence of HIV infection on clinical presentation, response to treatment, and outcome in adults with tuberculous meningitis. J Infect Dis 192:2134–2141CrossRefPubMedGoogle Scholar
  27. 27.
    Croda MG, Vidal JE, Hernández AV, Dal Molin T, Gualberto FA, Oliveira AC (2010) Tuberculous meningitis in HIV-infected patients in Brazil: clinical and laboratory characteristics and factors associated with mortality. Int J Infect Dis 14:e586–e591CrossRefPubMedGoogle Scholar
  28. 28.
    Jones BE, Young SMM, Antoniskis D, Davidson PT, Kramer F, Barnes PF (1993) Relationship of the manifestations of tuberculosis to CD4 cell counts in patients with human immunodeficiency virus infection. Am Rev Respir Dis 148:1292–1297PubMedGoogle Scholar
  29. 29.
    Yechoor VK, Shandera WX, Rodriguez P, Cate TR (1996) Tuberculous meningitis among adults with and without HIV infection. Experience in an urban public hospital. Arch Intern Med 156:1710–1716CrossRefPubMedGoogle Scholar
  30. 30.
    Vinnard C, Macgregor RR (2009) Tuberculous meningitis in HIV-infected individuals. Curr HIV/AIDS Rep 6:139–145CrossRefPubMedGoogle Scholar
  31. 31.
    van der Weert EM, Hartgers NM, Schaaf HS, Eley BS, Pitcher RD, Wieselthaler NA et al (2006) Comparison of diagnostic criteria of tuberculous meningitis in human immunodeficiency virus-infected and uninfected children. Pediatr Infect Dis J 25:65–69CrossRefPubMedGoogle Scholar
  32. 32.
    Karande S, Gupta V, Kulkarni M, Joshi A, Rele M (2005) Tuberculous meningitis and HIV. Indian J Pediatr 72:755–760CrossRefPubMedGoogle Scholar
  33. 33.
    Gnaore E, Sassan-Morokro M, Kassim S, Ackah A, Yesso G, Adjorlolo G et al (1993) A comparison of clinical features in tuberculosis associated with infection with human immunodeficiency viruses 1 and 2. Trans R Soc Trop Med Hyg 87:57–59CrossRefPubMedGoogle Scholar
  34. 34.
    Torok ME, Chau TT, Mai PP, Phong ND, Dung NT, Chuong LV et al (2008) Clinical and microbiological features of HIV-associated tuberculous meningitis in Vietnamese adults. PLOS One 3:e1772CrossRefPubMedGoogle Scholar
  35. 35.
    Schutte CM (2001) Clinical, cerebrospinal fluid and pathological findings and outcomes in HIV-positive and HIV-negative patients with tuberculous meningitis. Infection 29:213–217CrossRefPubMedGoogle Scholar
  36. 36.
    Thwaites GE, Chau TT, Farrar JJ (2004) Improving the bacteriological diagnosis of tuberculous meningitis. J Clin Microbiol 42:378–379CrossRefPubMedGoogle Scholar
  37. 37.
    Jarvis JN, Meintjes G, Williams A, Brown Y, Crede T, Harrison TS (2010) Adult meningitis in a setting of high HIV and TB prevalence: findings from 4,961 suspected cases. BMC Infect Dis 10:67CrossRefPubMedGoogle Scholar
  38. 38.
    Pai M, Lewinsohn DM (2005) Interferon-gamma assays for tuberculosis: is anergy the Achilles’ heel? Am J Respir Crit Care Med 172:519–521CrossRefPubMedGoogle Scholar
  39. 39.
    Patel VB, Singh R, Connolly C, Coovadia Y, Peer AK, Parag P et al (2010) Cerebrospinal T Cell responses aid the diagnosis of tuberculous meningitis in a HIV and TB endemic population. Am J Respir Crit Care Med 182:569–577. doi:10.1164/rccm.200912-1931OC Google Scholar
  40. 40.
    Patel VB, Bhigjee AI, Paruk HF, Singh R, Meldau R, Connolly C et al (2009) Utility of a novel lipoarabinomannan assay for the diagnosis of tuberculous meningitis in a resource-poor high-HIV prevalence setting. Cerebrospinal Fluid Res 6:13CrossRefPubMedGoogle Scholar
  41. 41.
    Reddy KP, Brady MF, Gilman RH, Coronel J, Navincopa M, Ticona E et al (2010) Microscopic observation drug susceptibility assay for tuberculosis screening before isoniazid preventive therapy in HIV-infected persons. Clin Infect Dis 50:997–999CrossRefGoogle Scholar
  42. 42.
    World Health Organization (2010) Treatment of tuberculosis: guidelines, 4th edn. (WHO/HTM/TB/2009.420) World Health Organization. http://whqlibdoc.who.int/publications/2010/9789241547833_eng.pdf. Accessed 6 Apr 2010
  43. 43.
    Khan FA, Minion J, Pai M, Royce S, Burman W, Harries AD, Menzies D (2010) Treatment of active tuberculosis in HIV-coinfected patients: a systematic review and meta-analysis. Clin Infect Dis 50:1288–1299CrossRefPubMedGoogle Scholar
  44. 44.
    Thwaites GE, Nguyen DB, Nguyen HD, Hoang TQ, Do TT, Nguyen TC et al (2004) Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med 351:1741–1751CrossRefPubMedGoogle Scholar
  45. 45.
    Thwaites G, Fisher M, Hemingway C, Scott G, Solomon T, Innes J (2009) British Infection Society guidelines for the diagnosis and treatment of tuberculosis of the central nervous system in adults and children. J Infect 59:167–187CrossRefPubMedGoogle Scholar
  46. 46.
    Pepper DJ, Marais S, Maartens G, Rebe K, Morroni C, Rangaka MX et al (2009) Neurologic manifestations of paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome: a case series. Clin Infect Dis 48:e96–e107CrossRefPubMedGoogle Scholar
  47. 47.
    World Health Organization (2009) Rapid advice: antiretroviral therapy for HIV infection in adults and adolescents. http://www.searo.who.int/LinkFiles/HIV-AIDS_Rapid_Advice_Adult_ART_Guidelines%28web%29.pdf. Accessed 28 May 2010
  48. 48.
    Lawn SD, Churchyard G (2009) Epidemiology of HIV-associated tuberculosis. Curr Opin HIV AIDS 4:325–333CrossRefPubMedGoogle Scholar
  49. 49.
    Atun RA, Lebcir RM, Drobniewski F, McKee M, Coker RJ (2007) High coverage with HAART is required to substantially reduce the number of deaths from tuberculosis: system dynamics simulation. Int J STD AIDS 18:267–273CrossRefPubMedGoogle Scholar
  50. 50.
    Schiffer JT, Sterling TR (2007) Timing of antiretroviral therapy initiation in tuberculosis patients with AIDS: a decision analysis. J Acquir Immune Defic Syndr 44:229–234CrossRefPubMedGoogle Scholar
  51. 51.
    Kaplan JE, Benson C, Holmes KH, Brooks JT, Pau A, Masur H (2009) Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 58(RR-4):1–20Google Scholar
  52. 52.
    Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Nair G, Bamber S et al (2010) Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med 362:697–706CrossRefPubMedGoogle Scholar
  53. 53.
    Müller M, Wandel S, Colebunders R, Attia S, Furrer H, Egger M (2010) Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis 10:251–261CrossRefPubMedGoogle Scholar
  54. 54.
    Valin N, Pacanowski J, Denoeud L, Lacombe K, Lalande V, Fonquernie L et al (2010) Risk factors for ‘unmasking immune reconstitution inflammatory syndrome’ presentation of tuberculosis following combination antiretroviral therapy initiation in HIV-infected patients. AIDS 24:1519–1525CrossRefPubMedGoogle Scholar
  55. 55.
    Marais S, Scholtz P, Pepper DJ, Meintjes G, Wilkinson RJ, Candy S (2010) Neuroradiological features of the tuberculosis-associated immune reconstitution inflammatory syndrome. Int J Tuberc Lung Dis 14:188–196PubMedGoogle Scholar
  56. 56.
    World Health Organization (2010) Drug-resistant tuberculosis now at record levels. http://www.who.int/mediacentre/news/releases/2010/drug_resistant_tb_20100318/en/index.html. Accessed 6 April 2010
  57. 57.
    World Health Organization (2010) Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. WHO/HTM/TB/2010.3. http://whqlibdoc.who.int/publications/2010/9789241599191_eng.pdf. Accessed 6 Apr 2010
  58. 58.
    Patel VB, Padayatchi N, Bhigjee AI, Allen J, Bhagwan B, Moodley AA et al (2004) Multidrug-resistant tuberculous meningitis in KwaZulu-Natal, South Africa. Clin Infect Dis 38:851–856CrossRefPubMedGoogle Scholar
  59. 59.
    Cecchini D, Ambrosioni J, Brezzo C, Corti M, Rybko A, Perez M et al (2007) Tuberculous meningitis in HIV-infected patients: drug susceptibility and clinical outcome. AIDS 21:373–374CrossRefPubMedGoogle Scholar
  60. 60.
    Cecchini D, Ambrosioni J, Brezzo C, Corti M, Rybko A, Perez M et al (2009) Tuberculous meningitis in HIV-infected and non-infected patients: comparison of cerebrospinal fluid findings. Int J Tuberc Lung Dis 13:269–271PubMedGoogle Scholar
  61. 61.
    Byrd TF, Davis LE (2007) Multidrug-resistant tuberculous meningitis. Curr Neurol Neurosci Rep 7:470–475CrossRefPubMedGoogle Scholar
  62. 62.
    Gurumurthy P, Ramachandran G, Hemanth Kumar AK, Rajasekaran S, Padmapriyadarsini C, Swaminathan S et al (2004) Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease. Antimicrob Agents Chemother 48:4473–4475CrossRefPubMedGoogle Scholar
  63. 63.
    Gurumurthy P, Ramachandran G, Hemanth Kumar AK, Rajasekaran S, Padmapriyadarsini C, Swaminathan S et al (2004) Malabsorption of rifampin and isoniazid in HIV-infected patients with and without tuberculosis. Clin Infect Dis 38:280–283CrossRefPubMedGoogle Scholar
  64. 64.
    Li J, Munsiff SS, Driver CR, Sackoff J (2005) Relapse and acquired rifampin resistance in HIV-infected patients with tuberculosis treated with rifampin- or rifabutin-based regimens in New York City, 1997–2000. Clin Infect Dis 41:83–91CrossRefPubMedGoogle Scholar
  65. 65.
    McIlleron H, Meintjes G, Burman WJ, Maartens G (2007) Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome. J Infect Dis 196(Suppl-1):S63–S75CrossRefPubMedGoogle Scholar
  66. 66.
    Dube MP, Holtom PD, Larsen RA (1992) Tuberculous meningitis in patients with and without human immunodeficiency virus infection. Am J Med 93:520–524CrossRefPubMedGoogle Scholar
  67. 67.
    Karstaedt AS, Valtchanova S, Barriere R, Crewe-Brown HH (1998) Tuberculous meningitis in South African urban adults. QJM 91:743–747CrossRefPubMedGoogle Scholar
  68. 68.
    World Health Organization (2010) Safety of BCG vaccine in HIV-infected children. http://www.who.int/vaccine_safety/topics/bcg/immunocompromised/Dec_2006/en/. Accessed 6 Apr 2010
  69. 69.
    Akolo C, Adetifa I, Shepperd S, Volmink J (2010) Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev 1:CD000171. doi:10.1002/14651858.CD000171.pub3
  70. 70.
    McShane H (2009) Vaccine strategies against tuberculosis. Swiss Med Wkly 139:156–160PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  1. 1.Department of NeurologyChhatrapati Shahuji Maharaj Medical UniversityLucknowIndia

Personalised recommendations